J&J's Centocor Buy Eyes Potential $4 Bil. ReoPro Market To Spur Stent Sales
This article was originally published in The Gray Sheet
Johnson & Johnson's $4.9 bil. stock acquisition of biotechnology firm Centocor is motivated in part by the potential for Centocor's antiplatelet monoclonal antibody-based drug ReoPro (abciximab) to boost sales of coronary stents by J&J's Cordis unit.
You may also be interested in...
Centocor's $250 mil. investment in studies to demonstrate the efficacy of its drug ReoPro in combination with coronary stents in percutaneous coronary interventions could be attractive to Johnson & Johnson, which reportedly has been in discussions to acquire the biotech firm.
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.